Literature DB >> 9295344

Avian retrovirus U3 and U5 DNA inverted repeats. Role Of nonsymmetrical nucleotides in promoting full-site integration by purified virion and bacterial recombinant integrases.

A C Vora1, R Chiu, M McCord, G Goodarzi, S J Stahl, T C Mueser, C C Hyde, D P Grandgenett.   

Abstract

The U3 and U5 termini of linear retrovirus DNA contain imperfect inverted repeats that are necessary for the concerted insertion of the termini into the host chromosome by viral integrase. Avian myeloblastosis virus integrase can efficiently insert the termini of retrovirus-like DNA donor substrates (480 base pairs) by a concerted mechanism (full-site reaction) into circular target DNA in vitro. The specific activities of virion-derived avian myeloblastosis virus integrase and bacterial recombinant Rous sarcoma virus (Prague A strain) integrase (approximately 50 nM or less) appear similar upon catalyzing the full-site reaction with 3'-OH recessed wild type or mutant donor substrates. We examined the role of the three nonsymmetrical nucleotides located at the 5th, 8th, and 12th positions in the U3 and U5 15-base pair inverted repeats for their ability to modify the full-site and simultaneously, the half-site strand transfer reactions. Our data suggest that the nucleotide at the 5th position appears to be responsible for the 3-5-fold preference for wild type U3 ends over wild type U5 ends by integrase for concerted integration. Additional mutations at the 5th or 6th position, or both, of U3 or U5 termini significantly increased (approximately 3 fold) the full-site reactions of mutant donors over wild type donors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9295344     DOI: 10.1074/jbc.272.38.23938

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  18 in total

Review 1.  Retroviral DNA integration.

Authors:  P Hindmarsh; J Leis
Journal:  Microbiol Mol Biol Rev       Date:  1999-12       Impact factor: 11.056

2.  Substrate sequence selection by retroviral integrase.

Authors:  H Zhou; G J Rainey; S K Wong; J M Coffin
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

3.  DNase protection analysis of retrovirus integrase at the viral DNA ends for full-site integration in vitro.

Authors:  A Vora; D P Grandgenett
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

4.  Correct integration of model substrates by Ty1 integrase.

Authors:  S P Moore; D J Garfinkel
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

5.  Biochemical and biophysical analyses of concerted (U5/U3) integration.

Authors:  Duane P Grandgenett; Sibes Bera; Krishan K Pandey; Ajaykumar C Vora; Jacob Zahm; Sapna Sinha
Journal:  Methods       Date:  2008-11-29       Impact factor: 3.608

6.  Identification of amino acids in HIV-1 and avian sarcoma virus integrase subsites required for specific recognition of the long terminal repeat Ends.

Authors:  Aiping Chen; Irene T Weber; Robert W Harrison; Jonathan Leis
Journal:  J Biol Chem       Date:  2005-11-18       Impact factor: 5.157

7.  Differential assembly of Rous sarcoma virus tetrameric and octameric intasomes is regulated by the C-terminal domain and tail region of integrase.

Authors:  Sibes Bera; Krishan K Pandey; Hideki Aihara; Duane P Grandgenett
Journal:  J Biol Chem       Date:  2018-09-05       Impact factor: 5.157

8.  Base-pair substitutions in avian sarcoma virus U5 and U3 long terminal repeat sequences alter the process of DNA integration in vitro.

Authors:  P Hindmarsh; M Johnson; R Reeves; J Leis
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

9.  Efficient concerted integration by recombinant human immunodeficiency virus type 1 integrase without cellular or viral cofactors.

Authors:  Sapna Sinha; Michael H Pursley; Duane P Grandgenett
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

10.  Assembly and catalysis of concerted two-end integration events by Moloney murine leukemia virus integrase.

Authors:  F Yang; M J Roth
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.